Jo M.,Kyoto Prefectural University of Medicine |
Yasui K.,Kyoto Prefectural University of Medicine |
Kirishima T.,Kyoto City Hospital |
Shima T.,Saiseikai Suita Hospital |
And 20 more authors.
Hepatology Research | Year: 2014
Aim: Sorafenib is the standard systemic therapy for patients with advanced hepatocellular carcinoma (HCC). We aimed to assess the efficacy and safety of sorafenib therapy in very elderly patients aged 80 years and older with advanced HCC. Methods: In a retrospective multicenter study in Japan, we reviewed 185 patients (median age, 71 years; 82% male; 95% Child-Pugh class A) with advanced HCC who received sorafenib therapy. Data were compared between 24 (13%) patients aged 80 years and older and 161 (87%) patients aged less than 80 years. We used propensity score matching to adjust for differences between the two groups. Results: Median overall survival was 10.6 months in all patients: 11.7 months in patients aged 80 years and older and 10.5 months in those aged less than 80 years. There were no significant differences in overall survival, tumor response, and frequency and severity of drug-related adverse events between patients aged 80 years and older and those aged less than 80 years in both the entire study cohort and the propensity-matched cohort. Conclusion: Sorafenib may be effective and well tolerated, even in patients with advanced HCC who are aged 80 years and older, as well as those aged less than 80 years. © 2014 The Japan Society of Hepatology.
Furumoto K.,Koseikai Takeda Hospital |
Kogire M.,Kishiwada City Hospital |
Lizuka N.,Kishiwada City Hospital
Japanese Journal of Cancer and Chemotherapy | Year: 2015
A 63-year-old man who complained of hematochezia underwent colonoscopy, and a type 2 tumor was detected at the Rs portion. The tumor was initially diagnosed as a poorly differentiated adenocarcinoma by biopsy. Laparoscopy-assisted anterior resection with regional lymphadenectomy was performed, and pathological examination showed the tumor was a neuroendocrine carcinoma (NEC) with muscular invasion and lymph node metastasis. The Ki-67 index of the tumor was more than 70%. This patient underwent adjuvant chemotherapy with capecitabine for 6 months and is now alive without recurrence, more than 40 months after surgery. Although the prognosis of NEC is generally poor, capecitabine might be effective as an adjuvant chemotherapy regimen after curative resection.
Sato D.,Arrhythmia Care Center |
Kitajima H.,Arrhythmia Care Center |
Mani H.,Arrhythmia Care Center |
Park C.-H.,Koseikai Takeda Hospital |
Chun Y.-H.,Arrhythmia Care Center
Journal of Arrhythmia | Year: 2013
We report the case of a 64-year-old man who had a permanent pacemaker with a unipolar silicone electrode positioned in the right ventricle in 1989 for sinus node dysfunction. On a routine checkup in June 2011, a 28-mm-diameter mass was discovered, which appeared to adhere to the tricuspid valve and the ventricular lead. The size of the mass did not change for the next 6 months, and the lead impedance was maintained at around 500-600 Ω. Because pacing failure was observed in January 2012, he underwent an urgent pacemaker check; however, the lead impedance was found not to have increased greatly (689 Ω). Nevertheless, the pacemaker lead was noted to be fractured at the tricuspid level. His echocardiogram showed new severe tricuspid regurgitation and a floating mass around the lead. We extracted the fractured lead, enucleated the tumor, replaced the tricuspid valve, and placed an epicardial lead. Macroscopic examination revealed that the tumor surrounded the fractured lead and covered the stump. Pathological examination revealed that the tumor was composed of fibrous connective tissue. We presumed that electric current continued to flow through the stump of the fractured unipolar lead to the generator, and this might have caused the limited increase in lead impedance. © 2013 Japanese Heart Rhythm Society.
Akita S.,Hiroshima University |
Hattori N.,Hiroshima University |
Masuda T.,Hiroshima University |
Horimasu Y.,Hiroshima University |
And 5 more authors.
Cancer Science | Year: 2015
Aminopeptidase N (APN/CD13) is involved in tumor cell invasion and tumor angiogenesis and is considered a promising therapeutic target in the treatment of cancer. To develop a novel monoclonal antibody-based cancer therapy targeting APN/CD13, we established a fully humanized anti-APN/CD13 monoclonal antibody, MT95-4. In vitro, MT95-4 inhibited APN/CD13 enzymatic activity on the tumor cell surface and blocked tumor cell invasion. B16 mouse melanoma cells stably expressing human APN/CD13 were also established and were inoculated s.c. or injected i.v. into nude mice. We found that expression of human APN/CD13 in murine melanoma cells increased the size of subcutaneous tumors, extent of lung metastasis and degree of angiogenesis in the subcutaneous tumors; these tumor-promoting and angiogenesis-promoting characteristics were reduced by the i.p. administration of MT95-4. To further verify the specificity of MT95-4 for neutralization of APN/CD13 activity, MT95-4 was administered into NOD/SCID mice inoculated s.c. with H1299 or PC14 cells, which exhibit high expression of APN/CD13, or with A549 cells, which exhibit weak expression of APN/CD13. MT95-4 reduced tumor growth and angiogenesis in mice bearing H1299-derived and PC14-derived tumors, but not in mice bearing A549-derived tumors. These results suggested that the antitumor and anti-angiogenic effects of MT95-4 were dependent on APN/CD13 expression in tumor cells. Given that MT95-4 is the first fully humanized monoclonal antibody against APN/CD13, MT95-4 should be recognized as a promising candidate for monoclonal antibody therapy against tumors expressing APN/CD13. © 2015 The Authors.
Taniguchi A.,Ritsumeikan University |
Furukawa A.,Tokyo Metroplitan University |
Kanasaki S.,Koseikai Takeda Hospital |
Tateyama T.,Ritsumeikan University |
Chen Y.-W.,Ritsumeikan University
Proceedings of the 2013 6th International Conference on Biomedical Engineering and Informatics, BMEI 2013 | Year: 2013
In this paper, we propose an automated method for assessment of small bowel contraction movement based on a three-dimensional zero-mean normalized cross correlation method (3D-ZNCC) with cine-MRI. The correlation value between frames is proportional to area change of the small bowel and the temporal area change can be used as a measure of the small bowel contraction movement. In the conventional two-dimensional zero-mean normalized correlation (2D-ZNCC) method, only frame A and frame B are used for calculation of correlation between frame A and frame B. Since a complex shape change of the intestine is irregular, it was difficult to detect contraction movement. In order to solve this problem, we propose to use 3D ZNCC, in which sequence frames are used for correlation calculations instead of single frame. Since not only spatial changes, but also temporal changes are included, we can detect the contraction movement correctly. Experimental results show that our method is better than conventional method. © 2013 IEEE.